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Abstract
Rationale—Lymphatic vasculature plays important roles in tissue fluid homeostasis maintenance
and in the pathology of human diseases. Yet, the molecular mechanisms that control lymphatic
vessel maturation remain largely unknown.
Objective—We analyzed the gene expression profiles of ex vivo isolated lymphatic endothelial
cells to identify novel lymphatic vessel expressed genes and we investigated the role of Sema3A
and neuropilin-1 (Nrp-1) in lymphatic vessel maturation and function.
Methods and results—Lymphatic and blood vascular endothelial cells from mouse intestine
were isolated using fluorescence-activated cell sorting and transcriptional profiling was
performed. We found that the axonal guidance molecules Sema3A and Sema3D were highly
expressed by lymphatic vessels. Importantly, we found that the semaphorin receptor Nrp-1 is
expressed on the perivascular cells of the collecting lymphatic vessels. Treatment of mice in utero
(E12.5-E16.5) with an antibody that blocks Sema3A binding to Nrp-1, but not with an antibody
that blocks VEGF-A binding to Nrp-1, resulted in a complex phenotype of impaired lymphatic
vessel function, enhanced perivascular cell coverage and abnormal lymphatic vessel and valve
morphology.
Conclusions—Together, these results reveal an unanticipated role of Sema3A/Nrp-1 signaling
in the maturation of the lymphatic vascular network likely via regulating the perivascular cell
coverage of the vessels thus affecting lymphatic vessel function and lymphatic valve development.
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Introduction
The lymphatic vascular system has important functions in tissue fluid homeostasis, immune
surveillance and dietary lipid absorption in the intestine1. Impairment of lymphatic vessel
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development and function leads to a number of human lymphedema syndromes, and
activation of lymphatic vessels plays an important role in chronic inflammation and in tumor
metastasis2–5. Despite these important functions, basic research into the molecular control of
lymphatic system development has been initiated rather recently, and our knowledge of the
molecular pathways involved remains limited. Lymphatic vessels first arise during mid-
gestation from the existing veins where a subpopulation of endothelial cells (ECs) buds and
migrates to form the primitive lymph sacs, which in mice develop into a network of
lymphatic vessels by day E14.56. The maturation of the lymphatic vessel network continues
into the first postnatal days and involves the formation of the larger collecting lymphatic
vessels. The collecting lymphatic vessels acquire a sparse coverage by smooth muscle cells
(SMCs) - which is absent from lymphatic capillaries - as well as intraluminal valves that
prevent lymph backflow during contraction of the collecting vessels7. Recent developmental
studies in knock-out mice have revealed several genes, in particular FOXC2, ephrinB2 and
integrin-alpha 97–9, that play important roles in the maturation of collecting lymphatic
vessels and in lymphatic valve development. Gene expression profiling studies of cultured
human lymphatic (LECs) versus blood vascular endothelial cells (BECs) have been
instrumental in identifying novel molecular players that mediate lymphatic development and
function10–12. However, cultured cells lack the distinct cues from the tissue
microenvironment13, 14. To address this issue, we have performed a comprehensive gene
expression profiling of mouse LECs and BECs that were isolated by high-speed cell sorting
directly from mouse tissue. We found that several semaphorin family members showed a
distinct expression pattern in blood versus lymphatic vessel endothelium. The semaphorins
represent a family of classical axon guidance cues15 that interact with neuropilin receptors,
single-pass membrane proteins with separate domains for semaphorin and vascular growth
factor binding16.
We report that the axonal guidance genes semaphorin 3A (Sema3A) and Sema3D are
expressed by lymphatic vessels in vivo. Importantly, we found that the semaphorin receptor
neuropilin-1 (Nrp-1) is expressed on perivascular cells that sparsely cover the lymphatic
vessels throughout the vessel development, and on the collecting lymphatic vessel valves
postnatally. Treatment of mice in utero with an antibody that blocks Sema3A binding to
Nrp-1, but not with an antibody that blocks VEGF-A binding to Nrp-1, resulted in reduced
lymphatic vessel function, abnormal morphology of the collecting lymphatic vessels and
valves, and aberrant SMC coverage of lymphatic vessels. Together, these results reveal an
unanticipated role of Sema3A/Nrp-1 signaling in the maturation of the lymphatic vascular
network.
Methods
An expanded Methods section is available in the Online ‘Supplemental Material’ at http://
circres.ahajournals.org.
Microarray analysis of ex vivo isolated colon LECs and BECs
Eight-weeks-old C57BL/6J mice were used to obtain colon tissue for the ex vivo cell
isolation of endothelial cells as previously described17. Briefly, tissue was enzymatically
digested, single-cell suspensions prepared and immunostained with endothelial and
leukocyte markers. FACS was performed using a FACSAria and the FACSDiva software
(BD Biosciences). Animal experiments were approved by the Kantonales Veterinaeramt
Zurich.
Cells were sorted directly into RLT Plus lysis buffer (Qiagen) supplemented with β-
mercaptoethanol. RNA was extracted with the RNeasy Plus Micro kit (Qiagen).
Amplification of RNA was performed with the Whole Transcriptome-Ovation Pico RNA
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Amplification System (NuGEN Technologies, San Carlos, CA). Biotin-labeled cDNA
targets were hybridized to GeneChip Mouse Genome 430 2.0 arrays and arrays scanned
according to manufacturer's protocol (Affymetrix Inc., Santa Clara, CA). Quality control and
summarization based on the MAS5.0 algorithm18, 19 were performed in R using the
simpleaffy package of BioConductor20, 21. Lists of differentially expressed probe sets were
produced with pairwise comparisons with pairs defined as LECs and BECs from the same
animal. Differentially expressed genes were selected if they passed t-test criteria (p≤0.01)
and showed at least 2-fold changes between the two groups. All experiments were designed
and all information was compiled in compliance with MIAME guidelines22. The array data
have been deposited in the National Center for Biotechnology Information (NCBI) Gene
Expression Omnibus (GEO) and are accessible through GEO Series accession no.
GSE22034.
Quantitative real-time PCR
Taqman Gene Expression Master Mix and assays (Applied Biosystems, Foster City, CA)
were used to determine the expression levels of VEGFR1 (Mm_01210866_m1), podoplanin
(Mm00494716_m1), LYVE-1 (Mm01280692_m1), Nrp-1 (Mm01253206_m1) and Nrp-2
(Mm00803099_m1) in sorted cells. Duplex reactions with beta-actin (4352341E) as
endogenous control were run under standard conditions. Power SYBR Green PCR Master
Mix (Applied Biosystems) and QuantiTect Primer Assays (Qiagen) were used to determine
the expression levels of Sema3A (QT00173971), Sema3D (QT00125874) and Sema3G
(QT1160887) with beta-actin as endogenous control (QT01136772). RNA was extracted
from primary human dermal microvascular LECs, BECs10, HUVECs (ScienCell, Carlsbad,
USA), human coronary artery endothelial cells (HCAECs) and pericytes (PromoCell,
Heidelberg, Germany) with the RNeasy Micro kit (Qiagen) and transcribed to cDNA using
the High Capacity cDNA Reverse Transcription Kit (Applied Biosystems). QuantiTect
Primer Assays for human Sema3A (QT00040936), Sema3D (QT00037023) and beta-actin
primers (forward: 5’-TCACCGAGCGCGGCT-3’, reverse: 5’-
TAATGTCACGCACGATTTCCC-3’) and TaqMan gene expression assays for Nrp-1
(Hs00826128_m1) and CD31 (Hs00169777_m1) were used. A 7900HT Fast Real-Time
PCR System (Applied Biosystems) was used for all qPCR experiments.
Immunohistochemistry
Serial sections of paraffin-embedded mouse colon were boiled in citric buffer for antigen
retrieval. After endogenous peroxidase block, sections were incubated in 1% Triton X-100
(Sigma Aldrich, Munich, Germany) and blocked. Immunostaining was performed with goat
anti-Sema3A antibody (C-17, Santa Cruz, Santa Cruz, CA), rabbit anti-LYVE-1 antibody
(gift from N. Gale, Regeneron Pharmaceuticals, Tarrytown NY) or control goat IgG,
followed by biotin-labeled secondary antibodies (Vector, Burlingame, CA). Streptavidin-
conjugated peroxidase was used with the AEC kit as a substrate (Vector).
In utero treatment of mice
Timed pregnancies were set up in FVB/N wild type mice. On days E12.5, E14.4 and E16.5
the pregnant females (3 per group) received intraperitoneal injections of 1.2 mg of anti-
Nrp-1A antibody, anti-Nrp-1B antibody23, 24 or the control mouse IgG antibody. Neonatal
mice were collected for analysis at day P5.5.
Lymphatic vessel tracing
Approximately 3 μl of 5 mg/ml FITC-dextran (Mw ~2000 kDa; Invitrogen) was injected
into the forelimb footpad of anaesthetized P5.5 mice (n=8 per group). After 2 min, forelimb
lymphatic vessels were imaged noninvasively using a stereomicroscope Lumar.V12 and
Jurisic et al. Page 3
Circ Res. Author manuscript; available in PMC 2013 August 03.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
AxioCam digital camera (Zeiss, Jena, Germany). After 15 min, the pups were sacrificed, the
overlaying skin was removed and the lymphatic vessels were imaged.
Whole-mount staining
Intestines with attached mesentery were collected from embryos or neonatal mice and fixed
in 4% PFA. Tissue was blocked for unspecific binding and permeabilized with Triton-X.
Antibodies used were mouse Cy3-conjugated anti-SMA (Sigma), goat anti-VEGFR3
(AF743, R&D Systems Abingdon, United Kingdom), rabbit anti-Prox1 (gift from K.
Alitalo), mouse anti-Nrp-1A23; goat anti-Nrp-1 (R&D Systems), hamster anti-CD31 (2H8
clone, Millipore, Billerica, MA, USA), goat anti-integrin-alpha 9 (R&D Systems), mouse
anti-FNIIIEA (clone FN-3E2, Sigma), rat anti-mouse CD31 (clone MEC 13.3, BD
Biosciences), and AlexaFluor 488, 555, 594 or 647-conjugated secondary antibodies
(Invitrogen). Tissues were mounted in Vectashield (Vector) onto chambered coverglasses
(Nunc, Rochester NY) for confocal imaging. For quantification of lymphatic valves, total
number of valves identified by staining for intergrin-alpha9 and FNEIIIA was determined in
five mesenteric vessels in 2–3 mice subjected to each type of treatment. One-way ANOVA
with Tukey’s multiple comparison post test was done to determine statistical significance.
Data are shown as mean ± SD. Whole-mount images were acquired with a LSM 710 FCS
confocal microscope and ZEN software (Zeiss) and processed with IMARIS software
(Bitplane AG, Zürich, Switzerland).
Pericyte culture and migration
Primary human pericytes isolated from placenta (PromoCell) were cultured according to the
manufacturer’s recommendations. Pericytes seeded onto chambered coverglass (Nunc) were
fixed in 4% PFA and permeabilized with 0.3% Triton-X. Thereafter, primary goat antibody
to Nrp-1 (clone C-19, Santa Cruz) or control goat IgG (Abcam, Cambridge, UK) were
applied, followed by an AlexaFluor 594 conjugated secondary antibody (Invitrogen) and
Hoechst bisbenzimide (Invitrogen). Images were acquired with a LSM 710 FCS confocal
microscope and ZEN software (Zeiss). Transwell migration assays were performed using
polycarbonate, 8 μm pore size-membrane 24-well plates (Corning Life sciences). 40,000
pericytes at passage 6–7 were seeded in serum-free medium onto the upper side of the insert
that was coated with 1 ug/ml fibronectin (Millipore) on the bottom side and blocked with
0.2% BSA. Cells were allowed to migrate for 3h to the lower chamber containing either 1%
FCS alone or also recombinant Sema3A (50, 100 or 200 ng/ml; R&D Systems) and Nrp-1A,
Nrp-1B or control mouse IgG antibodies (20 μg/ml). Non-migrated cells were mechanically
removed, migrated cells were stained with Hoechst and 5 random images were taken per
insert. Nuclei from 3 wells per condition were counted using the ImageJ program (National
Institutes of Health, Bethesda), and one-way ANOVA with Tukey’s multiple comparison
post test was done to determine statistical significance. Data are shown as mean ± SEM.
Results
Ex vivo isolation of pure populations of mouse LECs and BECs by high-speed cell sorting
In order to analyze the transcriptional programs of endothelial cells within their tissue
microenvironment, we developed a protocol for fast and efficient digestion of mouse colon
tissue and high-speed cell sorting of lymphatic and blood vascular endothelial cells.
Immunostained colon single-cell suspensions were sorted based on the expression of the
pan-endothelial marker CD31, the lymphatic marker podoplanin and the pan-leukocyte
marker CD45. Approximately 70% of sorted colon endothelial cells were blood vascular
endothelial cells (BECs; CD31+CD45−podoplanin−) and approximately 30% were lymphatic
endothelial cells (LECs; CD31+CD45−podoplanin+) (Figure 1A). Total RNA was extracted
from these cells and isothermal linear whole transcriptome amplification was applied25. By
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qPCR analysis of four animal-matched pairs of ex vivo isolated LECs and BECs, the blood
vessel marker VEGFR1 and the lymphatic markers podoplanin and LYVE-1 were shown to
be consistently differentially expressed in BECs versus LECs (Figure 1B), confirming the
specificity of the cell-sorting procedure. The cDNA generated by whole transcriptome
amplification of four animal-matched pairs of ex vivo isolated LECs and BECs was labeled
and hybridized to Affymetrix mouse microarray chips. High quality microarray results were
obtained from the small number of cells isolated from the mouse colon tissue (1000–2000
LECs and 2000–4000 BECs). The microarray analysis confirmed high expression levels of
lineage-specific genes such as podoplanin and Prox1 in LECs, and neuropilin-1 and von
Willebrand factor (vWf) in BECs (Table 1, Supplementary tables 1 and 2, GEO Series
accession no. GSE22034).
Semaphorin 3 family members and their receptors have a lineage-specific expression
pattern in blood vascular and lymphatic endothelium
In addition to known lineage-specific genes, the microarray analysis of ex vivo isolated
LECs and BECs also revealed lineage-specific expression of genes whose specific
expression by LECs or BECs was not previously reported. By microarray analysis we found
a more than 450-fold higher expression level of Sema3D and a more than 150-fold higher
expression level of Sema3A in LECs compared to BECs. Conversely, Sema3G had a more
than 900-fold and Nrp-1 a more than 1200-fold higher expression in BECs than in LECs
(Table 1). By real-time qPCR analysis of ex vivo isolated cells, we confirmed the high
expression levels of Sema3A and Sema3D in LECs, and of Sema3G and Nrp-1 in BECs. In
line with reports showing Nrp-2 expression on veins and lymphatic vessels26, comparable
expression levels of Nrp-2 were found in LECs and BECs indicating mixed venous and
arterial components in the BEC fraction (Figure 2A). We next tested by qPCR the
expression levels of Sema3A and Sema3D in cultured human endothelial cells. We found
that Sema3A had up to approximately 8-fold and Sema3D up to approximately 18-fold
higher expression levels in cultured human dermal microvascular LECs than in BECs, while
HCAECs showed low expression levels of both genes (Figure 2B). Immunohistochemical
analysis of Sema3A expression in mouse colon tissue confirmed that Sema3A protein is
indeed expressed by LYVE-1-positive lymphatic vessels (Figure 2C, arrowheads) but not by
LYVE-1-negative, erythrocyte-filled blood vessels (Figure 2C, asterisks).
Neuropilin-1 is expressed by the collecting lymphatic vessel perivascular cells and valves
Nrp-1 is the only currently known receptor for Sema3A. To identify the potential target cells
for lymphatic vessel-produced Sema3A, we next performed immunofluorescence analyses
of mouse mesenteric vessels at different developmental stages. We found that at E18.5 and
at P3 perivascular cells of the collecting vessels - most likely SMCs or pericytes - expressed
Nrp-1 (Figure 3A, first and second row, arrowheads). Interestingly at P6, we observed
expression of Nrp-1 on the perivascular cells (Figure 3A, third row, arrowheads) and in the
lymphatic vessel valves (Figure 3A, third row arrows). Immunofluorescence analyses of
whole-mount preparations of P7 mouse mesentery, stained for Nrp-1 and the lymphatic
markers Prox1 and VEGFR3 confirmed that besides expression on the arteries (Figure 3B,
asterisk), Nrp-1 is expressed in the lymphatic valves – characterized by a stronger
expression of VEGFR3 and Prox1 than the surrounding non-valve associated lymphatic
endothelium (Figure 3B, arrowheads). These results indicate that earlier in the development
of collecting lymphatic vessels lymphatic endothelium secreted Sema3A is affecting the
perivascular cells, while at the later stages lymphatic valve cells might be affected.
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In utero blockade of Sema3A binding to Nrp-1 results in decreased lymphatic vessel
function and lymphatic vessel morphological changes
We next investigated whether the interaction of Sema3A expressed by lymphatic vessels
with its receptor Nrp-1 on perivascular cell and on the lymphatic valves might play a
functional role during lymphatic vascular development. To this end, we treated pregnant
female FVB/N mice with antibodies that block Nrp-1 ligand binding. We used the anti-
Nrp-1A antibody which specifically blocks the binding of Sema3A to Nrp-1, as well as the
anti-Nrp-1B antibody which specifically blocks the binding of VEGF-A to Nrp-123, 24.
Antibodies or control IgG were injected between E12.5 and E16.5 - time points when the
lymphatic vascular network is maturing and when lymphatic valves start to form, while most
of the blood vascular development is already completed. Litter sizes were normal in all
treatment groups and no gross morphological abnormalities were observed in close
examinations of the offspring. Problems with motor function and coordination were not
observed in any of the treatment groups, excluding major effects of the treatment on the
nervous system. Pups treated with the anti-Nrp-1A antibody had mildly reduced body
weight when compered with control and anti-Nrp-1B-treated pups (Online Figure I).
We next analyzed whether the blockade of Sema3A binding to Nrp-1 might affect the
function of collecting lymphatic vessels. To this end, we injected large molecular weight
FITC-dextran into the forelimb fat pads of treated and control pups at day P5.5. In control
pups, FITC-dextran filled the deep large collecting vessel (Figure 4A, arrowhead) - ranging
from the foot to the brachial region - already after a few minutes, rendering it visible through
the skin. In contrast, in 5 out of 8 anti-Nrp-1A treated pups, the injected FITC-dextran was
drained through the superficial lymphatic vessel network (Figure 4A, arrows). This
alternative route of draining suggests that the collecting lymphatic vessels do not function
properly in the absence of the Sema3A signal.
To characterize the lymphatic vessel defects we performed immunofluorescence analysis of
the treated mice mesentery. Under normal conditions, at day P5.5 the mesenteric collecting
lymphatic vessels follow the branches of the mesenteric vein and artery as tubes with an
even diameter that is interrupted by subtle constrictions where the lymphatic valves are
located (Figure 4B, first and second row, Online Figure II A, first row). Such normal vessel
morphology was observed in mice that were treated in utero with control IgG and in mice
treated in utero with anti-Nrp-1B (which blocks VEGF-A binding to Nrp-1). Importantly, in
the anti-Nrp-1A-treated group (blockade of Sema3A binding to Nrp-1), a high proportion
(55.5%) of offspring had irregularly shaped collecting lymphatic vessels at day P5.5 (Figure
4B, third row, arrows; Online Figure II A, rows 2 to 4, arrowheads).
Large blood vessels in the mesentery, characterized by strong CD31 expression, were not
affected in any of the treatment groups (Figure 4B), most likely because development of
these vessels was completed before day E12.5. It is of interest that we found fewer blood
vessel capillaries in anti-Nrp-1B treated pups at day P5.5 (Online Figure III A and B),
indicating that the formation of smaller blood vessels is impaired when VEGF-A binding to
Nrp-1 is blocked, in line with previously reported effects of this antibody24. We also
analyzed vascular remodeling in the retina at day P5.5. We found no differences between the
control group and the anti-Nrp-1A group (Online Figure III C, D and E), in agreement with
previously reported results with this antibody at this time point 24.
After in utero blockade of Sema3A binding to Nrp-1, smooth muscle cells aberrantly cover
lymphatic vessels
While blood vessels are densely covered by smooth muscle cells (SMCs), initial lymphatic
vessels lack SMC coverage and collecting lymphatic vessels acquire only sparse SMC
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coverage - especially in the valve areas that are normally devoid of SMCs 7. The expression
of Nrp-1 by perivascular cells of the developing lymphatic vessels (Figure 3A) prompted us
to investigate whether aberrant SMC coverage might have contributed to the abnormal
morphology of collecting lymphatic vessels when Sema3A binding to Nrp-1 was blocked.
Thus, we studied the expression of alpha-smooth muscle actin (α-SMA) in the mesenteries
of the treated animals at day P5.5. In agreement with a previous report 7, at day P5.5
mesenteric lymphatic vessels were sparsely covered by SMCs (Figure 5A, Online Figure II
B, first row). Furthermore, the valve areas visible by a strong CD31 signal on the valve
leaflets were devoid of SMCs (Figure 5A, arrowheads). This normal phenotype was present
in the groups treated with control IgG and with anti-Nrp-1B antibody (Figure 5A, first and
second row). Importantly, we found that the collecting lymphatic vessels in anti-Nrp-1A-
treated animals had a more pronounced coverage by α-SMA-expressing cells, especially in
the valve areas (Figure 5A arrows, Online Figure II B, second row, arrowheads). Detailed
examination of the mesenteric lymphatic vessels of the treated animals revealed a significant
increase in the number of valve areas covered by SMCs only in the anti-Nrp-1A treated
group (Figure 5B).
Cultured primary human pericytes express high levels of Nrp-1 at the mRNA and protein
levels (Figure 5C and D). To investigate the possible mechanisms by which lymphatic
vessel-produced Sema3A might act on perivascular cells, we performed Transwell migration
assays and found that significantly fewer pericytes migrated to the lower chamber of the
well when Sema3A was added to the medium, and that this effect was abrogated by the
addition of the anti-Nrp-1A antibody (Figure 5E, **p<0.01). These results indicate that
Sema3A-Nrp1 signal is needed for the regulation of pericyte migration and that its
disruption likely leads to the ectopic SMC coverage phenotype observed in mice treated
with the anti-Nrp-1A antibody.
Blocking Sema3A-Nrp-1 axis indirectly causes lymphatic valve defects
In molecularly defined areas, the LEC monolayer in the collecting lymphatic vessels
remodels to form lymphatic valve structures essential for the proper lymphatic draining
function27. A closer examination of the lymphatic valves by immunofluorescence analyses
revealed that the valve markers integrin-alpha 9 and fibronectin EIIIA (FNEIIIA) uniformly
delineated the valve leaflets in mice treated with control IgG and anti-Nrp-1B antibody (Fig.
6A, first and second row). In contrast, integrin-alpha 9 was mislocalized, and increased and
diffuse FNEIIIA expression was present in a significant proportion of valves of mice treated
with anti-Nrp1A antibody (Figure 6A, third row). While the total number of valves did not
differ between groups (Figure 6B), the anti-Nrp-1A-treated group had a significantly
increased number of abnormal valves in the mesentery in comparison with the control group
and the anti-Nrp-1B treated group (Figure 6C, ***p<0.001). These results indicate that the
aberrant SMC coverage of the valve areas and the impaired lymphatic flow could result in
defective valve morphology.
Discussion
Recently, several axonal guidance molecules have been implicated to also play a role in
vascular system development and in the maintenance of proper vascular function16. In the
vascular system, neuropilin receptors have been investigated mainly for their property of
binding VEGF family ligands while their semaphorin binding property has been
predominantly linked to their functions in the development of the nervous system. The
present study for the first time reveals that lymphatic and blood vessels express different
members of the semaphorin family, and it identifies Sema3A as a novel molecular player in
the maturation of the lymphatic vessel network.
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In earlier reports, differences in the gene expression between in vitro cultured LECs and
BECs were analyzed using microarrays10, 12. However, the gene expression signature of
cultured endothelial cells significantly differs from their in vivo gene expression
signature13, 14. Here, we have for the first time analyzed the gene expression profiles of
LECs and BECs isolated directly from mouse colon tissue, and we were able to confirm the
purity of FACS sorted LECs and BECs by qPCR analysis of vascular lineage-specific genes
such as Prox1, podoplanin and VEGFR1. Surprisingly, we found dramatic differences in the
endothelial lineage-specific expression levels of several semaphorins since Sema3A and
Sema3D were exclusively detected in lymphatic vessel endothelium. Although Sema3A and
Sema3D were expressed more strongly in cultured lymphatic endothelial cells than in blood
vascular endothelial cells, in agreement with a recent report28, the differences in expression
levels between LECs and BECs were much more dramatic in ex vivo isolated cells. These
findings underline the need to perform analyses of endothelial cells directly from tissues and
also indicate that microenvironmental cues are needed to maintain the differential gene
expression signatures in vivo. Our findings of lineage-specific expression of several
semaphorin family members suggests that the function of the neuropilin-1 receptor on
vessels may also be modulated by binding of semaphorins, in addition to the binding of
VEGFs. In our quest to identify a potential role of Sema3A in the lymphatic vascular
system, we found - by immunofluorescence analyses - that the Sema3A receptor Nrp-1, in
addition to being abundant on arteries, was also expressed on the perivascular cells covering
the lymphatic vessels and on the lymphatic valves.
The Sema3A/Nrp-1 signaling axis is known to provide the repelling cues that ensure the
maintenance of boundaries during the pathfinding of axons in the nervous system29. On the
other hand Nrp-1 plays a crucial role in cardiovascular development. Both the general and
the endothelial-specific Nrp-1 deficiency results in embryonic lethality at around mid-
gestation30, 31, thus preventing studies of the effects of Nrp-1 deficiency on the lymphatic
vessel maturation. Previously, genetic manipulation and mutagenesis have been used to
selectively disrupt Sema3A-Nrp-1 signal in mice. It was found that neural development was
severely affected, whereas no major vascular defects were reported31, 32. It is of interest that
only 60% of Nrp-1Sema- mice survived until P7, and of those, only a few survived to
adulthood31. Therefore, the collecting lymphatic vessel defects identified in our study could
have easily been missed in these earlier studies, while the neuronal defects were avoided in
our study by timing the treatment to a late developmental stage. The effects of Sema3A
deficiency have been studied in several different genetic mouse backgrounds, and the
phenotypes ranged from embryonic lethal with vascular defects to viable with neuronal
defects15, 33. However a later detailed analysis of Sema3A deficient mice revealed no blood
vessel defects34. It will be of great interest to create endothelial or even lymphatic
endothelial-specific Sema3A deficient mice, to specifically investigate Sema3A effect on the
lymphatic vasculature.
The recent development of two antibodies that specifically block either VEGF-A or Sema3A
binding to Nrp-23 provided us with the unique opportunity to separately investigate the
effects of these two ligands on lymphatic vascular development. We timed the treatment
with the antibodies to avoid the embryonic lethality and the blood vascular defects that are
found in the various knock-out mice. Surprisingly, blockade of Sema3A, but not of VEGF-A
binding to Nrp-1 had a profound effect on the development of lymphatic vessels, leading to
their impaired maturation and function.
We showed that the perivascular cells express Nrp-1 in vivo and that Sema3A regulates
pericyte migration in vitro by binding to Nrp-1. Based on these results we propose a model
in which LEC-secreted Sema3A acts on the Nrp-1 expressing perivascular cells to ensure
that they do not cover lymphatic vessels in the valve areas and that they remain sparse
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elsewhere on the collecting vessels. Thus, the observed impaired lymphatic flow and
abnormal collecting lymphatic vessel morphology in anti-Nrp-1A antibody-treated mice
most likely arises due to the ectopic perivascular cell coverage in the valve areas. Similarly,
lack of FOXC2, which is first observed on the developing valves at day E15.5 and was
shown to interact with NFATc1 to orchestrate the valve formation7, was shown to result in
abnormal perivascular cell recruitment and subsequent abnormal lymphatic vessel
morphology35. Moreover, perivascular cells enable the autonomous lymphatic contraction
and flow as a response to tightly regulated nitric oxide production36, 37, so it is conceivable
that SMCs positioned on collecting lymphatic vessels are a part of the flow regulating
mechanism. After treatment with the anti-Nrp-1A antibody, we observed that the smaller
superficial lymphatic vessels filled with FITC-dextran. The underlying mechanism may be
that the smaller vessels provide an alternative draining route or that there is a backflow of
fluid from the larger vessel into the smaller vessels. Both mechanisms are indicative of
impaired lymphatic function.
The animals in which binding of Sema3A to Nrp-1 was blocked displayed a high number of
abnormally formed lymphatic valves. Considering that Nrp-1 expression was found in the
lymphatic valves only at P6 and 7 (Figure 3A and B) and the treatment was applied in utero
during the late embryonic development, we conclude that the valve defects most likely did
not arise from a direct effect of the blocking antibodies on the developing valve cells, but as
a consequence of the changes in the perivascular cell coverage and changes in the lymphatic
flow. Indeed, recently it was shown that the correctly established flow in the lymphatic
vessels is crucial for the lymphatic valve development 38.
Prox1 expression has been shown to be crucial for lymphatic and venous valve
specification7, 27, 38, 39. We found that Prox1 levels were not altered in the abnormal
lymphatic vessels and valves of anti-Nrp-1A treated mice, indicating that Sema3A-Nrp-1
signal is required at a later time point in valve development and does not affect valve
specification.
Importantly, although inhibition of the VEGF-A binding to Nrp-1 did not influence
lymphatic vessel development, the formation of small blood vessels was impaired, in
agreement with the previously reported effects of this antibody24 - therefore confirming the
activity of the antibody.
Class A plexins are neuropilin co-receptors for secreted semaphorins in the nervous
system40, 41. Our microarray studies revealed expression of several plexins by LECs and
BECs, making it conceivable that also in the lymphatic system plexins transduce signals
upon Sema3A binding. It would be of interest, to analyze lymphatic vessel development in
mice lacking the class 3 semaphorin plexin co-receptors42. Indeed, plexin A1, but not the
plexins A2, A3 or A4, is specifically expressed on the lymphatic valves (A. Eichmann,
personal communication), where it likely forms a complex with Nrp-1 to transduce a
repelling signal.
Taken together, our results identify the Sema3A/Nrp-1 axis as a novel player in lymphatic
vascular network maturation, and they point to potential new targets for therapies aimed at
modulating lymphatic vessel function.
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Novelty and significance
What is known
• Lymphatic vessels are crucial for maintaining tissue fluid homeostasis and play
important roles in human diseases, including lymphedema, chronic
inflammation and cancer metastasis.
• Collecting lymphatic vessels are only sparsely covered by pericytes, when
compared to blood vessels, and contain intraluminal lymphatic valves that
prevent backflow of fluid.
• Recent loss-of-functions studies revealed that the transcription factor FOXC2
and the integrin-alpha 9 play important roles in the control of lymphatic vessel
pericyte coverage and lymphatic valve formation.
What new information does this article contribute
• This article provides the first comprehensive analysis of the gene expression
profile of lymphatic versus blood vascular endothelial cells isolated directly
from mouse tissue and we reveal that several semaphorin 3 family genes show
differential expression in these two cell types.
• We show that lymphatic endothelium specifically produces semaphorin3A
(Sema3A) which acts on perivascular cells that express the Sema3A receptor
neuropilin-1 (Nrp-1).
• Blockade of Sema3A binding to Nrp-1 in vivo resulted in increased pericyte
coverage of lymphatic vessels, impaired lymphatic flow, and impaired
lymphatic valve formation, revealing an unanticipated function of the Sema3A/
Nrp1 axis in lymphatic maturation and function.
Despite the important function of the lymphatic vasculature in physiology, inflammation
and cancer, the molecular mechanisms that regulate its function remain poorly
characterized. To identify novel molecular players, we analyzed the transcriptional
profile of lymphatic versus blood vascular endothelial cells isolated directly from mouse
tissue.
We found that Sema3A was specifically expressed by lymphatic endothelium. Sema3A
promoted directed migration of perivascular cells that expressed its receptor Nrp-1. In
vivo blockade of the Sema3A/Nrp-1 interaction resulted in impaired lymphatic flow,
enhanced perivascular cell coverage and abnormal lymphatic vessel and valve
morphology.
Our findings, for the first time, identify the murine lymphatic versus blood vascular
transcriptome in vivo which strongly differed from results obtained in cultured cells,
revealing the importance of microenvironmental cues. The lineage-specific factors
identified will aid researchers in studying the function of the lymphatic and blood
vascular system in vivo. We also identified an important and unanticipated role of
Sema3A/Nrp1 signaling, previously thought to be mainly involved in nervous system
development, in the maturation and function of lymphatic vessels.
These findings should have broad future implications for basic vascular research and for
the potential development of therapeutic modalities for disorders such as lymphedema
and chronic inflammation.
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Figure 1. Ex vivo isolation of pure blood vascular and lymphatic endothelial cells from mouse
colon tissue by high-speed cell sorting
(A) Colon single-cell suspensions were immunostained for the pan-endothelial marker
CD31, the leukocyte marker CD45 and the lymphatic marker podoplanin. The
CD31+CD45− population was further separated into podoplanin+ LECs and podoplanin−
BECs. (B) qPCR for the blood vessel marker VEGFR1 and the lymphatic markers
podoplanin and LYVE-1 was performed on sorted LECs and BECs. Four animal-matched
pairs of LECs (gray bars) and BECs (white bars) showed consistent differential expression
levels. Beta-actin was used for normalization of the expression levels. Error bars show
standard deviation.
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Figure 2. Semaphorin 3 family members are expressed specifically by lymphatic or blood
vascular endothelium
(A) Specific expression of Sema3A and Sema3D by lymphatic endothelium, and of Sema3G
by blood vascular endothelium, as assessed by qPCR analysis of ex vivo isolated mouse
LECs and BECs. The semaphorin receptor Nrp-1 was expressed specifically by BECs and
Nrp-2 levels were similar in LECs and BECs. (B) Higher expression of Sema3A and
Sema3D by cultured human LECs than BECs and HCAECs. Beta-actin was used for
normalization of the expression levels. Error bars show standard deviation. (C)
Immunohistochemical analysis confirmed the expression of Sema3A in intestinal lymphatic
vessels (arrowheads). Serial paraffin sections of mouse colon tissue were immunostained
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with antibodies for Sema3A or LYVE-1, or with control goat IgG. Asterisk depicts a
LYVE-1-negative blood vessel that is also negative for Sema3A expression. Hematoxylin
counterstain. Scale bars: 100 μm.
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Figure 3. Nrp-1 is expressed on the developing collecting lymphatic vessel perivascular cells and
on lymphatic valves
(A) Mouse embryonic mesenteries at E18.5, P3 and P6 were immunostained for Prox1
(magenta), CD31 (green), Nrp-1 (red) and DAPI (blue). The high-magnification single
optical slice shows expression of Nrp-1 on lymphatic perivascular cells at E18.5, P3 and P6
(arrowheads). Additionally, at P6 there is an overlap of CD31 (green) and Nrp-1 on the
lymphatic valve (arrows). Representative images of 4 mesenteries per stage are shown. MIP
(maximum intensity projection) shows a 3D reconstruction of the image. Scale bars: 20 μm.
(B) Immunofluorescence analyses of P7 mouse mesentery whole-mount preparations. The
lymphatic markers VEGFR3 (magenta) and Prox1 (green) show stronger expression in the
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valve area (arrowheads) than in the remaining lymphatic vessel areas. Nrp-1 (red) signal was
found on the artery (asterisks) and in the valve area. The lower panel represents a higher
magnification of the upper panel. Images were obtained by confocal microscopy. Scale bars:
100 μm.
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Figure 4. Blockade of Sema3A/Nrp-1 signaling leads to impaired lymphatic vessel function and
abnormal morphology of developing collecting lymphatic vessels
(A) FITC-dextran (2000 kDa) was injected into the forelimb fat pad of control and of anti-
Nrp-1A treated pups at day P5.5 to visualize the draining lymphatic vasculature. Low
magnification images were taken through the skin and high magnification images were
taken after removal of the skin to reveal the lymphatic vessels in more detail. Arrowheads
point to the normal route of draining via the deep collecting lymphatic vessels. Arrows point
to the alternative draining route via the superficial lymphatic vessel network. Scale bars: 500
μm. (B) Whole-mount preparations of mesenteries immunostained for CD31 (green) and
VEGFR3 (magenta) were analyzed. When compared with control IgG-treated animals (first
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row) and anti-Nrp-1B-treated animals (second row), anti-Nrp-1A-treated animals had
abnormally formed collecting lymphatic vessels (third row, arrows). Scale bars: 50 μm, n=
13–18 mice per group.
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Figure 5. Smooth muscle cells (SMCs) aberrantly cover collecting lymphatic vessels after
Sema3A/Nrp-1 signal blocking, and Sema3A inhibits migration of Nrp-1 expressing pericytes in
vitro
(A) Alpha-smooth muscle actin (α-SMA, magenta) expressing SMCs normally sparsely
cover lymphatic vessels and are absent from the valve areas that are visible by a stronger
CD31 (green) staining (arrowheads). This phenotype was found in control and in anti-
Nrp-1B antibody treated mice at P5.5. Anti-Nrp-1A treatment resulted in excessive coverage
of collecting lymphatic vessels by SMCs in the valve areas (arrows). Scale bars: 50 μm. (B)
Quantification of the valve areas covered by SMCs in P5.5 in utero treated mice. n= 2–3
mesenteries per group, bars show mean ± standard deviation. Cultured primary human
pericytes express Nrp-1 as assessed by (C) immunofluorescence staining (scale bar: 10 μm),
and by (D) qPCR where pericytes showed low CD31 levels and Nrp-1 levels comparable to
those found in HUVEC (mean fold change ± standard deviation). (E) Sema3A prevents
migration of pericytes to 1% FCS and fibronectin coating. This effect was blocked by
incubation with the anti-Nrp-1A antibody but not with control IgG. A representative
experiment (out of 3) is shown. Bars show mean values ± SEM, one-way ANOVA Tukey’s
post test. **p<0.01.
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Figure 6. Blocking Sema3A-Nrp-1 signal indirectly causes abnormal lymphatic valve
morphology
(A) For lymphatic valve analysis, mesenteries were immunostained for integrin-alpha 9
(red) and fibronectin EIIIA (magenta). The white dotted line outlines the lymphatic vessels.
Scale bars: 20 μm. (B) The total number of valves per mesentery and (C) the number of
abnormal valves with excessive FNEIIIA deposition, integrin-alpha 9 mislocalization and
ring-shaped leaflets per mesentery were quantified. n=2–3 mice per group, bars show mean
values ± SD, one-way ANOVA Tukey’s post test. ***p < 0.001, ns=not significant.
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